Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunovaccine has signed a collaborative research program with the National Research Council Canada (NRC) to investigate the efficacy of a carbohydrate-based vaccine formulated in the company's proprietary vaccine delivery and enhancement platform, DepoVax.
Subscribe to our email newsletter
The collaboration aims to design a carbohydrate-based vaccine, using the DepoVax formulation, that can produce antibody levels specific to the carbohydrate target and capable of neutralizing meningococci.
The research is also expected to assess the ability of the carbohydrate-based vaccine candidate to kill cancer cells.
Under the pact, Immunovaccine’s DepoVax vaccine delivery and enhancement technology will formulate the carbohydrate antigen into liposomes and then in oil.
Immunovaccine R&D vice president Marc Mansour said that this modified carbohydrate is unique because of its potential utility as an antigen for both a bacterial vaccine and a therapeutic cancer vaccine.
"This is the first time we are incorporating a carbohydrate antigen into our DepoVax platform to further demonstrate its flexibility and versatility," Mansour said.